The MENDS2 Study, Maximizing the Efficacy of Sedation and Reducing Neurological Dysfunction and Mortality in Septic Patients With Acute Respiratory Failure



Status:Recruiting
Conditions:Cognitive Studies, Hospital, Neurology, Psychiatric, Pulmonary
Therapuetic Areas:Neurology, Psychiatry / Psychology, Pulmonary / Respiratory Diseases, Other
Healthy:No
Age Range:18 - Any
Updated:4/6/2019
Start Date:August 2012
End Date:September 2019
Contact:Pratik P. Pandharipande, MD, MSCI
Email:pratik.pandharipande@vanderbilt.edu
Phone:615-343-6268

Use our guide to learn which trials are right for you!

Altering Sedation Paradigms to Improve Brain Injury and Survival in Severe Sepsis

Ventilated ICU patients frequently have sepsis and the majority have delirium, a form of
brain dysfunction that is an independent predictor of increased risk of dying, length of
stay, costs, and prolonged cognitive impairment in survivors. Universally prescribed sedative
medications—the GABA-ergic benzodiazepines—worsen this brain organ dysfunction. The available
alternative sedation regimens, the shorter acting GABA-ergic propofol, and the alpha2
agonist, dexmedetomidine, have both been shown to be superior to benzodiazepines, and yet are
different with regard to their effects on innate immunity, bacterial clearance, apoptosis,
cognition and delirium. The MENDS2 study will compare propofol and dexmedetomidine, and
determine the best sedative medication to reduce delirium and improve survival and long-term
brain function in our most vulnerable patients— the ventilated septic patient.

The need for mechanical ventilation (MV) secondary to sepsis is the leading cause of
admission to the intensive care unit, often necessitating sedation for patient safety and
comfort. Recently, we have learned that these sedative medications contribute to iatrogenic
injury, such as prolonging ventilator time and ICU length of stay and exacerbating acute
brain dysfunction. This acute brain dysfunction, manifested as delirium and coma, occurs in
50%-70% of MV septic patients and is a significant contributor not only to death but also to
functional and cognitive decline, which can persist for years after recovery of lung and
other organ function, levying significant costs to patients and society. Despite advances in
the management of acute respiratory failure and sepsis, few clinical trials have examined the
effects that supportive therapies, like sedation, may have on both short- and long-term
outcomes in this vulnerable population. The gamma-aminobutyric acid (GABA)-ergic
benzodiazepines, in particular, have been shown to increase brain dysfunction, promote
infection, and prolong MV. Therefore, the short-acting GABA-ergic sedative propofol and the
alpha2 agonist dexmedetomidine are becoming widely used to sedate septic MV patients. There
are only a few randomized trials, however, to guide clinicians when selecting between these
and other sedatives, and none have explored the mechanisms underlying the differences in
outcomes, though some data indicate that GABA-ergic and alpha2 agonist agents have very
different effects on innate immunity, apoptosis, arousability, and respiratory drive. In
early animal and human studies, dexmedetomidine had more anti-inflammatory effects than the
GABA-ergic agents; dexmedetomidine improved bacterial clearance, whereas propofol impaired
it. In addition, sedation with dexmedetomidine instead of benzodiazepines reduces delirium by
20%-30% and improves arousability, cognition, and attentiveness in ventilated patients.
Alpha2 agonists induce unconsciousness at the brainstem—more akin to natural sleep—which may
improve autonomic function and immunity. All these factors converge to suggest that sedation
with an alpha2 agonist rather than a GABAergic agent may improve outcomes, including brain
function, MV, and survival, for septic MV patients. We therefore propose the MENDS2
(Maximizing the Efficacy of Sedation and Reducing Neurological Dysfunction and Mortality in
Septic Patients with Acute Respiratory Failure) study, in which we will test the hypotheses
that sedation of MV severely septic patients with an alpha2 agonist (dexmedetomidine) rather
than a GABAergic agent (propofol) will (Aim 1A) increase days alive without delirium or coma,
(Aim 1B) increase ventilator-free days, (Aim 2A) improve 90-day survival, (Aim 2B) decrease
long-term cognitive impairment, and (Aim 3) reduce the pro-inflammatory cytokine cascade
following sepsis. We will randomize 420 ventilated, severely septic patients requiring
goal-directed sedation with dexmedetomidine or propofol, giving the study 85% power to detect
a difference of 1.5 delirium/coma-free days and an absolute difference in mortality of 12%
between the two groups.

Inclusion Criteria:

Consecutive patients will be eligible for inclusion in the MENDS2 study if they are: [1]
adult patients (≥18 years old) [2] in a medical and/or surgical ICU and [3] on MV and
requiring sedation and [4] have suspected or known infection

Exclusion Criteria:

Patients will be excluded (i.e., not consented) for any of the following reasons:

1. Rapidly resolving organ failure, indicated by planned immediate discontinuation of MV,
at time of screening for study enrollment

2. Pregnant or breastfeeding

3. Severe dementia or neurodegenerative disease, defined as either impairment that
prevents the patient from living independently at baseline or IQCODE >4.5, measured
using a patient's qualified surrogate. This exclusion also pertains to mental
illnesses requiring long-term institutionalization, acquired or congenital mental
retardation, severe neuromuscular disorders, Parkinson's disease, and Huntington's
disease. It also excludes patients in coma or with severe deficits due to structural
brain diseases such as stroke, intracranial hemorrhage, cranial trauma, malignancy,
anoxic brain injury, or cerebral edema.

4. History of 2nd or 3rd degree heart block, bradycardia < 50 beats/minute, pacemaker for
bradyarrythmias or uncompensated shock.If patient has a pacemaker for bradyarrythmias,
then patient does not meet this exclusion criterion and may be enrolled.

5. Benzodiazepine dependency or history of alcohol dependency based on the medical team's
decision to institute a specific treatment plan involving benzodiazepines (either as
continuous infusions or intermittent intravenous boluses) for this dependency.

6. Active seizures during this ICU admission being treated with intravenous
benzodiazepines.

7. Expected death within 24 hours of enrollment or lack of commitment to aggressive
treatment by family/medical team (e.g., likely to withdraw life support measures
within 24 hrs of screening)

8. Inability to understand English or deafness or vision loss that will preclude delirium
evaluation. The inability to understand English (for example in Spanish-only or
Mandarin-only speaking patients) will not result in exclusion at centers where the
research staff is proficient and/or translation services are actively available in
that particular language; these patients will not be followed in the long-term
follow-up phase of the trial since the testing materials are primarily available only
in English. Patients with laryngectomies and those with hearing deficits are eligible
for enrollment if their medical condition permits them to communicate with research
staff.

9. Inability to obtain informed consent from an authorized representative within 48 hours
of meeting all inclusion criteria, i.e., developing sepsis and qualifying organ
dysfunction criteria for the following reasons:

1. Attending physician refusal.

2. Patient and/or surrogate refusal.

3. Patient unable to consent and no surrogate available.

4. 48-hour period of eligibility was exceeded before the patient was screened.

10. Prisoners.

11. Medical team following patient unwilling to use the sedation regimens.

12. Documented allergy to propofol or dexmedetomidine.

13. Current enrollment in a study that does not allow co-enrollment or that uses delirium
as a primary outcome.

14. Patients who are on muscle relaxant infusions at time of screening with plans to
maintain paralysis >48 hours.

15. Greater than 96 hours on mechanical ventilation prior to meeting all inclusion
criteria.
We found this trial at
11
sites
Asheville, North Carolina 28801
Principal Investigator: Gregg Stashenko, MD, MHS
?
mi
from
Asheville, NC
Click here to add this to my saved trials
800 Washington St
Boston, Massachusetts 02111
(617) 636-5000
Principal Investigator: John Devlin, Pharm.D
Phone: 617-373-8171
Tufts Medical Center Tufts Medical Center is an internationally-respected academic medical center – a teaching...
?
mi
from
Boston, MA
Click here to add this to my saved trials
1200 Moursund Street
Houston, Texas 77030
(713) 798-4951
Principal Investigator: Kalpalatha Guntupalli, MD
Phone: 713-798-2435
Baylor College of Medicine Baylor College of Medicine in Houston, the only private medical school...
?
mi
from
Houston, TX
Click here to add this to my saved trials
1211 Medical Center Dr
Nashville, Tennessee 37232
(615) 322-5000
Principal Investigator: Christopher Hughes, MD
Phone: 615-343-6268
Vanderbilt Univ Med Ctr Vanderbilt University Medical Center (VUMC) is a comprehensive healthcare facility dedicated...
?
mi
from
Nashville, TN
Click here to add this to my saved trials
4502 Medical Drive
San Antonio, Texas 78284
(210) 567-7000
Principal Investigator: Antonio R. Anzueto, MD
Phone: 210-617-5256
University of Texas Health Science Center at San Antonio The University of Texas Health Science...
?
mi
from
San Antonio, TX
Click here to add this to my saved trials
8415 Goodwood Blvd # 200
Baton Rouge, Louisiana 70806
Principal Investigator: Hollis R O'Neal, Jr., MD
Phone: 225-757-4070
?
mi
from
Baton Rouge, LA
Click here to add this to my saved trials
1301 Pennsylvania Avenue
Fort Worth, Texas 76104
Principal Investigator: Allison Snyder, MSN, APRN, ACNS-BC, CCRN
Phone: 817-250-6350
?
mi
from
Fort Worth, TX
Click here to add this to my saved trials
6550 Fannin St
Houston, Texas 77030
(713) 790-3311
Principal Investigator: Joshua Swan, Pharm.D, BCPS
Phone: 713-441-0165
Houston Methodist Hospital Houston Methodist is comprised of a leading academic medical center in the...
?
mi
from
Houston, TX
Click here to add this to my saved trials
Madison, Wisconsin 53792
(608) 263-2400
University of Wisconsin In achievement and prestige, the University of Wisconsin–Madison has long been recognized...
?
mi
from
Madison, WI
Click here to add this to my saved trials
San Francisco, California 94143
Principal Investigator: Michael A. Gropper, MD, PhD
Phone: 415-353-1212
?
mi
from
San Francisco, CA
Click here to add this to my saved trials
759 Chestnut Street
Springfield, Massachusetts 01199
(413) 794 - 0000
Principal Investigator: Patrick T. Mailloux, MD
Phone: 413-794-2419
Baystate Medical Center Baystate Medical Center (BMC), in Springfield, Massachusetts, is an academic, research, and...
?
mi
from
Springfield, MA
Click here to add this to my saved trials